Relationship between plasminogen activator inhibitor-1 gene alterations and fibrosis in peritoneal dialysis patients.

Autor: Onur Cura D; Faculty of Medicine, Department of Medical Genetics, Dokuz Eylul University, Izmir, Turkey., Yildiz S; Faculty of Medicine, Department of Nephrology, Dokuz Eylul University, Izmir, Turkey., Ataman E; Faculty of Medicine, Department of Medical Genetics, Dokuz Eylul University, Izmir, Turkey., Ersan S; Department of Nephrology, Tepecik Education and Research Hospital, University of Health Sciences, İzmir, Turkey., Tanrisev M; Department of Nephrology, Tepecik Education and Research Hospital, University of Health Sciences, İzmir, Turkey., Ulgenalp A; Faculty of Medicine, Department of Medical Genetics, Dokuz Eylul University, Izmir, Turkey., Camsari T; Faculty of Medicine, Department of Nephrology, Dokuz Eylul University, Izmir, Turkey., Ercal D; Faculty of Medicine, Department of Pediatric Genetics, Dokuz Eylul University, Izmir, Turkey.
Jazyk: angličtina
Zdroj: Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy [Ther Apher Dial] 2021 Feb; Vol. 25 (1), pp. 97-102. Date of Electronic Publication: 2020 Jun 01.
DOI: 10.1111/1744-9987.13501
Abstrakt: Peritoneal fibrosis (PF) is a pathological change that occurs mostly long-term peritoneal dialysis (PD) patients, as a result of triggering the inflammatory response. Plasminogen activator inhibitor-1 (PAI-1) is an important molecule featured in the development of fibrosis. It has been shown in literature that PAI-1 gene alterations are associated with fibrosis in many tissues and organs. However, PAI-1 gene alterations in long-term PD patients have not yet been investigated. In this study, PAI-1 4G/5G polymorphism was examined by reverse hybridization, and all coding exons of the PAI-1 gene were examined by sequence analysis to provide treatment modification in patients with predisposition before fibrosis develops. The patients were divided into two groups according to ultrafiltration failure test and duration of PD treatment: those with suspected PF or a high probability of developing PF (36%) and those with a low probability of developing PF (64%). There was no significant difference between the two groups in findings such as peritoneal equilibration test (PET), Kt/V, the content of the PD solution used, peritonitis, and PAI-1 4G/5G polymorphism (P > .05). A total of eight gene alterations (rs2227660, rs2227668, rs2854233, rs41281004, rs61553169, rs368413856, rs2227684) were detected by sequence analysis, one of which was exonic (rs6092). When the genotype distributions of these variants were examined, no significant difference was found between the two groups. PAI-1 gene changes were not detected in patients with the probability of developing PF. There is a need for further studies involving other molecules responsible for predisposing to PF with larger patient populations in patients undergoing long-term PD treatment.
(© 2020 International Society for Apheresis, Japanese Society for Apheresis, and Japanese Society for Dialysis Therapy.)
Databáze: MEDLINE
Externí odkaz: